Search
Ranolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[A189234] Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. … [L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440]
Cefpiramide
go.drugbank.com/drugs/DB00430ApprovedCefpiramide is a third-generation cephalosporin antibiotic.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseEchothiophate
go.drugbank.com/drugs/DB01057ApprovedInvestigationalA potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Insulin glulisine
go.drugbank.com/drugs/DB01309ApprovedIf left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening … Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.
Categories: Insulins and Analogues for Injection, Fast-ActingProducts: Apidra SoloStar 100 Units/ml Solution for injection in a pre-filled pen, APIDRA SOLOSTAR 100 UNITS/ML, SOLUTION FOR INJECTION IN A PRE-FILLED PENUmbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnUnfortunately, many patients experience a relapse or develop resistance to these drugs. … While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigationalMethyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. … [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects.
Categories: Aromatic L-amino Acid Decarboxylase Inhibitors, Antihypertensive Agents Indicated for HypertensionSynonyms: L-Methyl Dopa, α-methyl-L-dopaBrinzolamide
go.drugbank.com/drugs/DB01194ApprovedBrinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase II (CA-II) inhibitor indicated to reduce ocular pressure in patients with ocular hypertension or open-angle glaucoma. … [A2049,A2051] Although systemic anti-carbonic anhydrase (CA) therapy has been used for almost 50 years with varying degrees of success, systemic administration results in an increase in incidences of adverse
Products: BRINZOLAMID AL 10MG/ML, BRINZOLAMID 1A PHAR10MG/MLTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTF is a novel target for cancers, as it is often overexpressed on solid tumours, including cervical cancer, and it is associated with poor clinical outcomes. … TF is a primary initiator of the extrinsic blood coagulation cascade [L38424] and plays a key role in tumor-associated angiogenesis, progression, and metastasis for tumor survival.
Asunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnAsunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. … It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseMobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnMobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic